Abstract: Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting wild type c-kit kinase and for treating disorders and diseases mediated by wild type c-kit kinase in humans or non-humans.

Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: A telescoping mirror pivot assembly comprises a telescoping frame assembly, a central shaft, and a mirror head. The telescoping frame assembly may include a first end and a second end. The central shaft may be coupled to the first end of the telescoping frame assembly. The central shaft may include a detent manual fold arm. The detent manual fold arm may comprise a first detent and a second detent. The first detent may be configured to mechanically secure the telescoping frame assembly in a first position. The second detent may be configured to mechanically secure the telescoping frame assembly in a second position. The mirror head may be coupled to the second end of the telescoping frame assembly. The telescoping frame assembly may be configured to transition from the first position to the second position when a first force is applied in a first direction to the mirror head.

Abstract: One variation of a method includes: receiving identification of a patient associated with an encounter via a provider portal accessed by a provider; accessing a health record for the patient; accessing a diagnostic model including a module corresponding to a diagnosis; extracting a set of patient indicators, supporting the diagnosis for the patient, from the health record; and deriving a confidence score for the diagnosis for the patient. The method further includes, in response to the confidence score exceeding a threshold score: appending a list of predicted diagnoses with the diagnosis; and transmitting a prompt to the provider, via the provider portal, to review the list of predicted diagnoses.

Abstract: One variation of a method includes: receiving identification of a diagnosis for an encounter with a patient via a provider portal accessed by a provider; accessing a health record for the patient; accessing a diagnostic model including a module corresponding to the diagnosis; extracting a set of patient indicators, supporting the diagnosis for the patient, from the health record; and transmitting a prompt to the provider, via the provider portal, to review each patient indicator for specifying in a provider note generated for the encounter. This variation of the method further includes, in response to receiving selection of a subset of patient indicators, for specifying in the provider note, from the provider: appending the provider note with the subset of patient indicators; predicting an acceptance score for the provider note; and, in response to the acceptance score exceeding a threshold score, verifying the provider note.

Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Abstract: The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: The present disclosure provides a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: The present disclosure provides a compound represented by structural formula (I): (I), or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting wild type c-kit kinase and for treating disorders and diseases mediated by wild type c-kit kinase in humans or non-humans.

Abstract: A method for managing aircraft storage comprises observing an aircraft, identifying the aircraft, identifying a leasehold that can store the aircraft, adding the aircraft to a hangar space in the leasehold, updating a hangar Roll Call, and providing insights and analytics to a fixed base operator. A system for managing aircraft storage comprises a network, one or more local and external data sources or methods configured to provide aircraft data operated or performed by a fixed-base operator or third-party respectively, and an aircraft management server that automatically generates aircraft entries based on the aircraft data. The aircraft management server can also identify one or more aircraft, determine a space in a leasehold capable of holding the aircraft, and assign a Roll Call record for the one or more aircraft. The aircraft entries or Roll Call record are accessible to a user using an electronic device via a user interface.

Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Abstract: A non-pneumatic tire is provided that has a hub with a central axis. A supporting structure is located outward from the hub in a radial direction, and a shear band is located outward from the supporting structure in the radial direction. Tread is located outward from the shear band in the radial direction. A static discharge element extends from a first radial end of the supporting structure to a second radial end of the supporting structure. The first radial end is located closer to the central axis than the second radial end in the radial direction. The static discharge element is electrically conductive to conduct electricity through the supporting structure.